title: Sarcoidosis or foreign-body granulomatous reaction during interferon treatment?
authors.forename: Davide
authors.initials: D
authors.lastname: Bitetto
authors.forename: Elisa
authors.initials: E
authors.lastname: Fumolo
authors.forename: Carlo
authors.initials: C
authors.lastname: Fabris
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Toniutto
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects; D003357:Cosmetic Techniques / Q000009:adverse effects; D005260:Female; D005549:Foreign-Body Reaction / Q000209:etiology*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012307:Risk Factors; D012507:Sarcoidosis / Q000209:etiology*; D012871:Skin Diseases / Q000209:etiology*; D013653:Tattooing / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D001672:Biocompatible Materials; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a